Market open
$
19.62
Change
+0.60 +3.15%
Volume
Volume 91,177
Feb 6, 2023, 11:00 a.m.
Real time quotes
Previous close
$ 19.02
$ 19.62
Change
+0.60 +3.15%
Day low
Day high
$18.90
$19.68

52 week low
52 week high
$10.81
$21.25

Market cap
$787.75M
Average volume
756,698
P/E ratio
3.40
Rev. per Employee
$755,906
EPS
5.74
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on ICPT
-
Madrigal Pharmaceuticals Stock More Than Doubles on 'NASH' Breakthrough
- Barron's Online
-
Two Years Later, Intercept Takes Another Run at NASH
- Barron's Online
-
Intercept Pharmaceuticals stock price target cut to $31 from $43 at Canaccord Genuity
- Tomi Kilgore
-
The FDA's Biogen Decision Will Cause Waves Across Biotech
- Barron's Online
-
Intercept Pharmaceuticals downgraded to neutral from buy at B. Riley
- Tomi Kilgore
-
Intercept Pharmaceuticals stock price target cut to $74 from $97 at B. Riley FBR
- Tomi Kilgore
-
Intercept Pharmaceuticals upgraded to outperform from market perform at Raymond James
- Tomi Kilgore
-
Intercept shares gain after it announces layoffs
- Jaimy Lee
-
A Top Contender Drops Out of Race for a NASH Drug
- Barron's Online
-
Biogen Submits Troubled Alzheimer’s Drug for FDA Approval
- Barron's Online
-
Analysts Are Downgrading Intercept Pharmaceuticals. Here’s Why.
- Barron's Online
-
Intercept Pharmaceuticals downgraded to market perform at BMO Capital
- Tomi Kilgore
-
Intercept Pharmaceuticals stock price target cut to $97 from $158 at B. Riley FBR
- Tomi Kilgore
-
Intercept Pharmaceuticals stock price target cut to $50 from $89 at SVB Leerink
- Tomi Kilgore
-
Intercept Shares Tumble on NASH Disappointment
- Barron's Online
- Loading more headlines...
Analyst Ratings
-
Analysts Are Bullish on Viking Therapeutics Stock
- MarketRealist.com
-
Benzinga's Top Upgrades, Downgrades For November 2, 2017
- Benzinga.com
-
Benzinga's Top Upgrades, Downgrades For October 4, 2017
- Benzinga.com
Other News on ICPT
-
Intercept updates Phase 3 data for the NASH candidate
- Seeking Alpha
-
Intercept updates Phase 3 data for the NASH candidate
- Seeking Alpha
-
Intercept updates Phase 3 data for the NASH candidate
- Seeking Alpha
-
Intercept updates Phase 3 data for the NASH candidate
- Seeking Alpha
-
Intercept Pharmaceuticals: Trying Times
- Seeking Alpha
-
10-Q: INTERCEPT PHARMACEUTICALS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
MNSO and CLEU among mid-day movers
- Seeking Alpha
-
Intercept Pharma rises 12% on strong Q3 sales of Ocaliva therapy
- Seeking Alpha
-
Notable earnings before Tuesday's open
- Seeking Alpha
-
Akero: Putting Together The Pieces They Let Us See
- Seeking Alpha
- Loading more headlines...
Press Releases on ICPT
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com